Life Technologies, Bioheart Team on Stem Cell Research Offering | GenomeWeb
NEW YORK (GenomeWeb News) – Bioheart, a Sunrise, Fla.-based developer of stem cell therapies for cardiovascular diseases, today said that it has entered into a global distribution and OEM pact for Life Technologies to sell the firm’s myoblast cell-based research products to life science researchers.
Bioheart said that the myoblast products will complement Life Technologies’ current portfolio of reagents for isolating, characterizing, expanding, and differentiating stem cells.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: role for Notch signaling in congenital heart disease, sciatica risk variants, and more.

Researchers in China have used the CRISPR/Cas9 genome editing approach to alter the length of hair fibers in cashmere goats.

According to ScienceInsider, the Scripps Research Institute and the California Institute for Biomedical Research are merging.

National Cancer Institute researchers didn't report severe adverse events to Food and Drug Administration in a timely manner, the Wall Street Journal reports.